A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line

Figure 8

Expression of BRD-4 and c-Myc proteins. Exposure of MDA-MB-231 to ITH-47 + ESE-15-ol resulted in a decrease in both BRD4 (0.5-fold) and c-Myc (0.7-fold) protein levels when compared to all other treatment groups. indicates value <0.05 while indicates value <0.01.